Market Closed -
Hong Kong S.E.
04:08:42 2024-06-28 am EDT
|
5-day change
|
1st Jan Change
|
0.395
HKD
|
0.00%
|
|
+8.22%
|
-14.13%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
4,238
|
3,645
|
3,360
|
1,584
|
1,724
|
Enterprise Value (EV)
1 |
3,579
|
3,200
|
3,325
|
1,707
|
1,833
|
P/E ratio
|
-19.3
x
|
-19.7
x
|
-11.5
x
|
-7.52
x
|
-8.24
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
301
x
|
160
x
|
40.5
x
|
28.3
x
|
19.8
x
|
EV / Revenue
|
254
x
|
140
x
|
40.1
x
|
30.5
x
|
21
x
|
EV / EBITDA
|
-20.7
x
|
-21.7
x
|
-12.7
x
|
-9.29
x
|
-12.2
x
|
EV / FCF
|
-15.6
x
|
-19.3
x
|
-10
x
|
-6.94
x
|
-23.6
x
|
FCF Yield
|
-6.43%
|
-5.17%
|
-9.96%
|
-14.4%
|
-4.23%
|
Price to Book
|
4.02
x
|
4.13
x
|
5.58
x
|
3.95
x
|
8.41
x
|
Nbr of stocks (in thousands)
|
4,124,080
|
4,124,080
|
4,124,080
|
4,124,080
|
4,124,080
|
Reference price
2 |
1.028
|
0.8837
|
0.8148
|
0.3842
|
0.4181
|
Announcement Date
|
4/24/20
|
4/21/21
|
4/21/22
|
4/20/23
|
4/18/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
23.93
|
14.07
|
22.78
|
82.88
|
55.92
|
87.16
|
EBITDA
1 |
-108
|
-172.7
|
-147.2
|
-262.8
|
-183.7
|
-150.1
|
EBIT
1 |
-119.7
|
-187.2
|
-163.4
|
-297.5
|
-226.3
|
-202
|
Operating Margin
|
-500.23%
|
-1,330.07%
|
-717.48%
|
-358.97%
|
-404.61%
|
-231.74%
|
Earnings before Tax (EBT)
1 |
-152.6
|
-202.5
|
-184.6
|
-291.7
|
-210.8
|
-209.4
|
Net income
1 |
-124.9
|
-202.5
|
-184.6
|
-291.7
|
-210.8
|
-209.4
|
Net margin
|
-521.93%
|
-1,439.03%
|
-810.54%
|
-352%
|
-377.01%
|
-240.19%
|
EPS
2 |
-0.0600
|
-0.0533
|
-0.0448
|
-0.0707
|
-0.0511
|
-0.0508
|
Free Cash Flow
1 |
-92.86
|
-230
|
-165.4
|
-331
|
-245.9
|
-77.63
|
FCF margin
|
-388.11%
|
-1,634.43%
|
-726.11%
|
-399.4%
|
-439.68%
|
-89.07%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/17/19
|
4/24/20
|
4/21/21
|
4/21/22
|
4/20/23
|
4/18/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
123
|
109
|
Net Cash position
1 |
80.1
|
660
|
444
|
35.1
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.6682
x
|
-0.7276
x
|
Free Cash Flow
1 |
-92.9
|
-230
|
-165
|
-331
|
-246
|
-77.6
|
ROE (net income / shareholders' equity)
|
-74.3%
|
-31.1%
|
-19.1%
|
-39.3%
|
-42%
|
-69.1%
|
ROA (Net income/ Total Assets)
|
-19.6%
|
-12.5%
|
-7.98%
|
-18%
|
-15.6%
|
-12.9%
|
Assets
1 |
636.3
|
1,618
|
2,313
|
1,618
|
1,355
|
1,619
|
Book Value Per Share
2 |
0.0700
|
0.2600
|
0.2100
|
0.1500
|
0.1000
|
0.0500
|
Cash Flow per Share
2 |
0.0600
|
0.1400
|
0.1200
|
0.0200
|
0.0100
|
0.0400
|
Capex
1 |
52.8
|
114
|
197
|
149
|
125
|
19
|
Capex / Sales
|
220.62%
|
806.94%
|
865.9%
|
179.37%
|
223.77%
|
21.85%
|
Announcement Date
|
5/17/19
|
4/24/20
|
4/21/21
|
4/21/22
|
4/20/23
|
4/18/24
|
|
1st Jan change
|
Capi.
|
---|
| -14.13% | 209M | | +16.01% | 122B | | +19.13% | 113B | | +18.95% | 26.49B | | -23.46% | 19.4B | | -19.03% | 16.24B | | -20.21% | 15.4B | | -46.14% | 15.15B | | +63.78% | 14.93B | | +4.38% | 13.52B |
Bio Therapeutic Drugs
|